what is a glp 1 drug made from Glucagon-like peptide-1 Can one drug do it
Description
The beneficial actions based on activation of the entero-insular axis are complex and multitargeted, involving the gut, brain, pancreas, and liver
Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes
For these patients, basal insulin alone may not be the preferred option
The sustained success of Eliquis is further supported by its patent protections, which have delayed generic competition in the US until at least 2026, and potentially until 2031
